RITUXIMAB EFFICACY IN TREATING SYSTEMIC JUVENILE ARTHRITIS REFRACTORY TO TRADITIONAL IMMUNOSUPPRESSANT AND TNF BLOCKER THERAPY

RITUXIMAB EFFICACY IN TREATING SYSTEMIC JUVENILE ARTHRITIS REFRACTORY TO TRADITIONAL IMMUNOSUPPRESSANT AND TNF BLOCKER THERAPY

Show other versions (1)

<em>The article describes the clinical case of a difficult systemic juvenile arthritis refractory to traditional immunosuppressant and TNF blocker therapy. The disease was characterized by such extra-articulate manifestations as fever, lymphadenopathy, hepatolienomegaly, polyorrhymenitis, gene...

Full description

Bibliographic Details
Main Authors: E.I. Alexeeva, S.S. Akulova, E.L. Semikina, T.M. Bzarova, K.B. Isaeva
Format: Article
Language:English
Published: "Paediatrician" Publishers LLC 2007-01-01
Series:Voprosy Sovremennoj Pediatrii
Online Access:http://vsp.spr-journal.ru:80/jour/article/view/1232
id doaj-f84dbd5e53d445b3a1fca47baf7232c5
record_format Article
spelling doaj-f84dbd5e53d445b3a1fca47baf7232c52020-11-25T01:05:23Zeng"Paediatrician" Publishers LLC Voprosy Sovremennoj Pediatrii1682-55271682-55352007-01-0163941001232RITUXIMAB EFFICACY IN TREATING SYSTEMIC JUVENILE ARTHRITIS REFRACTORY TO TRADITIONAL IMMUNOSUPPRESSANT AND TNF BLOCKER THERAPYE.I. Alexeeva0S.S. Akulova1E.L. Semikina2T.M. Bzarova3K.B. Isaeva4Scientific Center of Children's Health, Russian Academy of Medical Sciences, MoscowScientific Center of Children's Health, Russian Academy of Medical Sciences, MoscowScientific Center of Children's Health, Russian Academy of Medical Sciences, MoscowScientific Center of Children's Health, Russian Academy of Medical Sciences, MoscowScientific Center of Children's Health, Russian Academy of Medical Sciences, Moscow<em>The article describes the clinical case of a difficult systemic juvenile arthritis refractory to traditional immunosuppressant and TNF blocker therapy. The disease was characterized by such extra-articulate manifestations as fever, lymphadenopathy, hepatolienomegaly, polyorrhymenitis, generalized joint affection and high laboratory activity indicators (ESR, CRP). The inclusion of rituximab stimulated the remission of systemic manifestations and the joint syndrome, as well as normalized the laboratory disease activity indicators. The therapeutic effect duration was 22 weeks upon the initial infusion of rituximab. The results demonstrate that rituximab is a promising medication for treating systemic juvenile arthritis children.</em><br /><strong><em>Key words: children, treatment, rituximab, juvenile arthritis.</em></strong>http://vsp.spr-journal.ru:80/jour/article/view/1232
collection DOAJ
language English
format Article
sources DOAJ
author E.I. Alexeeva
S.S. Akulova
E.L. Semikina
T.M. Bzarova
K.B. Isaeva
spellingShingle E.I. Alexeeva
S.S. Akulova
E.L. Semikina
T.M. Bzarova
K.B. Isaeva
RITUXIMAB EFFICACY IN TREATING SYSTEMIC JUVENILE ARTHRITIS REFRACTORY TO TRADITIONAL IMMUNOSUPPRESSANT AND TNF BLOCKER THERAPY
Voprosy Sovremennoj Pediatrii
author_facet E.I. Alexeeva
S.S. Akulova
E.L. Semikina
T.M. Bzarova
K.B. Isaeva
author_sort E.I. Alexeeva
title RITUXIMAB EFFICACY IN TREATING SYSTEMIC JUVENILE ARTHRITIS REFRACTORY TO TRADITIONAL IMMUNOSUPPRESSANT AND TNF BLOCKER THERAPY
title_short RITUXIMAB EFFICACY IN TREATING SYSTEMIC JUVENILE ARTHRITIS REFRACTORY TO TRADITIONAL IMMUNOSUPPRESSANT AND TNF BLOCKER THERAPY
title_full RITUXIMAB EFFICACY IN TREATING SYSTEMIC JUVENILE ARTHRITIS REFRACTORY TO TRADITIONAL IMMUNOSUPPRESSANT AND TNF BLOCKER THERAPY
title_fullStr RITUXIMAB EFFICACY IN TREATING SYSTEMIC JUVENILE ARTHRITIS REFRACTORY TO TRADITIONAL IMMUNOSUPPRESSANT AND TNF BLOCKER THERAPY
title_full_unstemmed RITUXIMAB EFFICACY IN TREATING SYSTEMIC JUVENILE ARTHRITIS REFRACTORY TO TRADITIONAL IMMUNOSUPPRESSANT AND TNF BLOCKER THERAPY
title_sort rituximab efficacy in treating systemic juvenile arthritis refractory to traditional immunosuppressant and tnf blocker therapy
publisher "Paediatrician" Publishers LLC
series Voprosy Sovremennoj Pediatrii
issn 1682-5527
1682-5535
publishDate 2007-01-01
description <em>The article describes the clinical case of a difficult systemic juvenile arthritis refractory to traditional immunosuppressant and TNF blocker therapy. The disease was characterized by such extra-articulate manifestations as fever, lymphadenopathy, hepatolienomegaly, polyorrhymenitis, generalized joint affection and high laboratory activity indicators (ESR, CRP). The inclusion of rituximab stimulated the remission of systemic manifestations and the joint syndrome, as well as normalized the laboratory disease activity indicators. The therapeutic effect duration was 22 weeks upon the initial infusion of rituximab. The results demonstrate that rituximab is a promising medication for treating systemic juvenile arthritis children.</em><br /><strong><em>Key words: children, treatment, rituximab, juvenile arthritis.</em></strong>
url http://vsp.spr-journal.ru:80/jour/article/view/1232
work_keys_str_mv AT eialexeeva rituximabefficacyintreatingsystemicjuvenilearthritisrefractorytotraditionalimmunosuppressantandtnfblockertherapy
AT ssakulova rituximabefficacyintreatingsystemicjuvenilearthritisrefractorytotraditionalimmunosuppressantandtnfblockertherapy
AT elsemikina rituximabefficacyintreatingsystemicjuvenilearthritisrefractorytotraditionalimmunosuppressantandtnfblockertherapy
AT tmbzarova rituximabefficacyintreatingsystemicjuvenilearthritisrefractorytotraditionalimmunosuppressantandtnfblockertherapy
AT kbisaeva rituximabefficacyintreatingsystemicjuvenilearthritisrefractorytotraditionalimmunosuppressantandtnfblockertherapy
_version_ 1725194856880406528

Similar Items